NANOTECHNOLOGY IN CANCER DRUG DELIVERY

Cancer treatment is often limited by the inability to deliver an effective drug concentration to malignant tissue without damaging healthy organs. Many anticancer medicines have poor water solubility, are rapidly removed from the circulation, or cause serious adverse effects because they distribute throughout the body. Nanotechnology offers a way to modify drug delivery by packaging medicines in very small carriers and controlling their circulation, tissue distribution and release. This review summarizes the main biological barriers encountered by nanoparticles, important lipid, polymeric, inorganic and biomimetic carrier systems, and methods used to target tumors. It also discusses carriers that respond to changes in pH, redox state, enzymes, temperature, light or ultrasound. Current applications include delivery of conventional anticancer drugs, immunemodulating agents, RNA and gene-editing systems, as well as combined imaging and treatment. Clinically used products demonstrate that nanocarriers can improve formulation properties and, in selected settings, reduce toxicity or improve therapeutic performance. However, variable tumor accumulation, immune recognition, manufacturing complexity, long-term safety and patient-topatient differences remain important obstacles. Better biological models, quality control, companion diagnostics and data-guided formulation design may help translate promising systems into reliable treatments.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24362579
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

NANOTECHNOLOGY IN CANCER DRUG DELIVERY

Kaufiya D. Sayyad, Koli Kunal
Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
article

NANOTECHNOLOGY IN CANCER DRUG DELIVERY

Kaufiya D. Sayyad, Koli Kunal
article en

Abstract

Cancer treatment is often limited by the inability to deliver an effective drug concentration to malignant tissue without damaging healthy organs. Many anticancer medicines have poor water solubility, are rapidly removed from the circulation, or cause serious adverse effects because they distribute throughout the body. Nanotechnology offers a way to modify drug delivery by packaging medicines in very small carriers and controlling their circulation, tissue distribution and release. This review summarizes the main biological barriers encountered by nanoparticles, important lipid, polymeric, inorganic and biomimetic carrier systems, and methods used to target tumors. It also discusses carriers that respond to changes in pH, redox state, enzymes, temperature, light or ultrasound. Current applications include delivery of conventional anticancer drugs, immunemodulating agents, RNA and gene-editing systems, as well as combined imaging and treatment. Clinically used products demonstrate that nanocarriers can improve formulation properties and, in selected settings, reduce toxicity or improve therapeutic performance. However, variable tumor accumulation, immune recognition, manufacturing complexity, long-term safety and patient-topatient differences remain important obstacles. Better biological models, quality control, companion diagnostics and data-guided formulation design may help translate promising systems into reliable treatments.

Zenodo (CERN European Organization for Nuclear Research)
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon